The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non‐small‐cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD‐1) and its ligand (PD‐L1), have remarkable antitumor efficacy and have...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cdt3.19 |
| _version_ | 1797839743408406528 |
|---|---|
| author | Fajiu Li Ying Chen Juanjuan Wu Chenghong Li Shi Chen Ziyang Zhu Wei Qin Min Liu Bingzhu Hu Shuang Liu Wenzhao Zhong |
| author_facet | Fajiu Li Ying Chen Juanjuan Wu Chenghong Li Shi Chen Ziyang Zhu Wei Qin Min Liu Bingzhu Hu Shuang Liu Wenzhao Zhong |
| author_sort | Fajiu Li |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non‐small‐cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD‐1) and its ligand (PD‐L1), have remarkable antitumor efficacy and have been approved as a standard first‐ or second‐line treatment in non‐oncogene‐addicted advanced NSCLC. The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long‐term overall survival and curative rates. In this review, we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer. We reviewed the early‐phase results from neoadjuvant clinical trials, the landscape of the majority of ongoing phase III trials, and discuss the prospects of ICIs as a curative therapy for resectable lung cancer. We also summarized the potential biomarkers and beneficiaries involved in the current study, as well as the remaining unresolved challenges for neoadjuvant immunotherapy. |
| first_indexed | 2024-04-09T16:03:04Z |
| format | Article |
| id | doaj.art-99580d1e6dba48c09b62e6fc5eeafb2d |
| institution | Directory Open Access Journal |
| issn | 2589-0514 |
| language | English |
| last_indexed | 2024-04-09T16:03:04Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Chronic Diseases and Translational Medicine |
| spelling | doaj.art-99580d1e6dba48c09b62e6fc5eeafb2d2023-04-25T08:06:27ZengWileyChronic Diseases and Translational Medicine2589-05142022-06-018210011110.1002/cdt3.19The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancerFajiu Li0Ying Chen1Juanjuan Wu2Chenghong Li3Shi Chen4Ziyang Zhu5Wei Qin6Min Liu7Bingzhu Hu8Shuang Liu9Wenzhao Zhong10Department of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of Jianghan University Wuhan Hubei ChinaGuangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou Guangdong ChinaAbstract Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non‐small‐cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD‐1) and its ligand (PD‐L1), have remarkable antitumor efficacy and have been approved as a standard first‐ or second‐line treatment in non‐oncogene‐addicted advanced NSCLC. The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long‐term overall survival and curative rates. In this review, we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer. We reviewed the early‐phase results from neoadjuvant clinical trials, the landscape of the majority of ongoing phase III trials, and discuss the prospects of ICIs as a curative therapy for resectable lung cancer. We also summarized the potential biomarkers and beneficiaries involved in the current study, as well as the remaining unresolved challenges for neoadjuvant immunotherapy.https://doi.org/10.1002/cdt3.19immune checkpoint inhibitorsneoadjuvant treatmentnon‐small‐cell lung cancer |
| spellingShingle | Fajiu Li Ying Chen Juanjuan Wu Chenghong Li Shi Chen Ziyang Zhu Wei Qin Min Liu Bingzhu Hu Shuang Liu Wenzhao Zhong The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer Chronic Diseases and Translational Medicine immune checkpoint inhibitors neoadjuvant treatment non‐small‐cell lung cancer |
| title | The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer |
| title_full | The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer |
| title_fullStr | The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer |
| title_full_unstemmed | The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer |
| title_short | The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer |
| title_sort | earlier the better a review of neoadjuvant immunotherapy in resectable non small cell lung cancer |
| topic | immune checkpoint inhibitors neoadjuvant treatment non‐small‐cell lung cancer |
| url | https://doi.org/10.1002/cdt3.19 |
| work_keys_str_mv | AT fajiuli theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT yingchen theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT juanjuanwu theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT chenghongli theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT shichen theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT ziyangzhu theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT weiqin theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT minliu theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT bingzhuhu theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT shuangliu theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT wenzhaozhong theearlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT fajiuli earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT yingchen earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT juanjuanwu earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT chenghongli earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT shichen earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT ziyangzhu earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT weiqin earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT minliu earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT bingzhuhu earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT shuangliu earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer AT wenzhaozhong earlierthebetterareviewofneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer |